Lineage Cell Therapeutics FY2028 EPS Decreased by B. Riley

Key Points

• B. Riley has revised its earnings per share (EPS) estimate for Lineage Cell Therapeutics for FY2028 from $0.20 to $0.15, while the consensus estimate remains at ($0.12) per share.
• Analysts have a consensus "Buy" rating for Lineage Cell Therapeutics, with price targets ranging from $2.00 to $9.00 per share.
• Lineage Cell Therapeutics' stock is currently trading at $1.20, with a 52-week range between $0.37 and $1.31.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Equities research analysts at B. Riley decreased their FY2028 earnings estimates for Lineage Cell Therapeutics in a research note issued on Friday, August 15th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.15 for the year, down from their previous estimate of $0.20. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics' FY2029 earnings at $0.11 EPS.

LCTX has been the topic of several other reports. D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Thursday, August 14th. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $4.25.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN LCTX traded up $0.03 during mid-day trading on Monday, hitting $1.20. The stock had a trading volume of 723,110 shares, compared to its average volume of 1,602,745. Lineage Cell Therapeutics has a 1 year low of $0.3651 and a 1 year high of $1.31. The business has a 50 day moving average price of $1.02 and a two-hundred day moving average price of $0.71. The firm has a market cap of $274.03 million, a P/E ratio of -6.67 and a beta of 1.66.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Hudson Bay Capital Management LP bought a new position in shares of Lineage Cell Therapeutics during the 2nd quarter valued at approximately $44,000. Brevan Howard Capital Management LP bought a new position in shares of Lineage Cell Therapeutics during the 2nd quarter valued at approximately $281,000. Raymond James Financial Inc. grew its stake in shares of Lineage Cell Therapeutics by 136.2% during the 2nd quarter. Raymond James Financial Inc. now owns 69,380 shares of the company's stock valued at $63,000 after acquiring an additional 40,009 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Lineage Cell Therapeutics during the 2nd quarter valued at approximately $35,000. Finally, WINTON GROUP Ltd bought a new position in shares of Lineage Cell Therapeutics during the 2nd quarter valued at approximately $69,000. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.